- Home
- XP vs MDGL Comparison
XP vs MDGL Comparison
Compare XP & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XP
- MDGL
- Stock Information
- Founded
- XP 2001
- MDGL 2011
- Country
- XP Cayman Islands
- MDGL United States
- Employees
- XP N/A
- MDGL N/A
- Industry
- XP Investment Bankers/Brokers/Service
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- XP Finance
- MDGL Health Care
- Exchange
- XP Nasdaq
- MDGL Nasdaq
- Market Cap
- XP 8.6B
- MDGL 9.6B
- IPO Year
- XP 2019
- MDGL N/A
- Fundamental
- Price
- XP $18.26
- MDGL $405.69
- Analyst Decision
- XP Strong Buy
- MDGL Strong Buy
- Analyst Count
- XP 5
- MDGL 12
- Target Price
- XP $22.40
- MDGL $521.09
- AVG Volume (30 Days)
- XP 6.4M
- MDGL 287.6K
- Earning Date
- XP 11-18-2025
- MDGL 11-04-2025
- Dividend Yield
- XP 7.57%
- MDGL N/A
- EPS Growth
- XP 18.07
- MDGL N/A
- EPS
- XP 1.67
- MDGL N/A
- Revenue
- XP $3,085,301,717.00
- MDGL $515,547,000.00
- Revenue This Year
- XP $16.93
- MDGL $394.38
- Revenue Next Year
- XP $11.96
- MDGL $64.73
- P/E Ratio
- XP $10.90
- MDGL N/A
- Revenue Growth
- XP 6.65
- MDGL 3421.98
- 52 Week Low
- XP $10.82
- MDGL $238.04
- 52 Week High
- XP $20.64
- MDGL $463.63
- Technical
- Relative Strength Index (RSI)
- XP 57.71
- MDGL 38.93
- Support Level
- XP $17.90
- MDGL $393.61
- Resistance Level
- XP $18.55
- MDGL $434.98
- Average True Range (ATR)
- XP 0.48
- MDGL 18.18
- MACD
- XP 0.20
- MDGL -3.40
- Stochastic Oscillator
- XP 83.55
- MDGL 19.81
About XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.